Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shared an update on Elevidys (delandistrogene moxeparvovec-rokl), the only approved ...

With a volume of 1,234,594, the price of SRPT is down -6.84% at $58.2. RSI indicators hint that the underlying stock may be ...

Sarepta Therapeutics (SRPT) stock drops as the EU officials request a clinical hold on trials involving its gene therapy ...

In a report released today, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Sarepta Therapeutics (SRPT – Research ...

In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), with a price ...

Fintel reports that on April 2, 2025, HC Wainwright & Co. upgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) ...

Fintel reports that on March 31, 2025, RBC Capital downgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) from ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $127.72, a high estimate of $202.00, and a low estimate of $75.00. This current ...

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) was downgraded by stock analysts at Royal Bank of Canada from an ...

Shares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 10.8% in the afternoon session after RBC analyst Brian Abrahams downgraded the stock from a Buy to a Hold rating and slashed the ...

Sarepta stock may recover sharply as additional information and data reveal that the adverse event reported by the company is isolated. Learn more on SRPT stock here.

We advise investors with a long-term horizon to remain invested in Sarepta stock, given its encouraging commercial portfolio and robust pipeline potential.